Tumor-derived circulating exosomal miR-342-5p and miR-574-5p as promising diagnostic biomarkers for early-stage Lung Adenocarcinoma.
diagnostic biomarker
exosomal miRNA
exosome
lung adenocarcinoma
Journal
International journal of medical sciences
ISSN: 1449-1907
Titre abrégé: Int J Med Sci
Pays: Australia
ID NLM: 101213954
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
12
2019
accepted:
15
05
2020
entrez:
7
7
2020
pubmed:
7
7
2020
medline:
9
3
2021
Statut:
epublish
Résumé
Lung cancer has been the leading cause of cancer morbidity and mortality in recent years. Most lung cancers are often asymptomatic until advanced or metastatic stage. Therefore, looking for the diagnostic biomarker for early-stage lung cancer is quite significant. Circulating exosomal microRNAs (miRNAs) have been reported to be the diagnostic and prognostic markers of various cancers. Here, we obtained circulating exosomal miRNA repertoires of 7 early-stage lung adenocarcinoma patients including pre-operation and post-operation (LA-pre and LA-post) and 7 heathy controls (HCs) by next generation sequence (NGS) and selected miR-342-5p, miR-574-5p and miR-222-3p to validate in ampliative samples by reverse transcription-quantitative PCR (RT-qPCR). Circulating exosomal miR-342-5p, miR-574-5p and miR-222-3p not only significantly elevated in LA patients (n = 56) compared with HCs (n = 40), but also significantly decreased after tumor resection when analyzed 51 paired pre- and post-operation samples. Furthermore, miR-342-5p and miR-574-5p, but not miR-222-3p, had a significantly elevated expression level in carcinoma tissue compared with adjacent non-cancerous tissue (n = 8). The receiver operating characteristic (ROC) curve showed the area under the curve (AUC) of combined miR-342-5p and miR-574-5p was 0.813 (95% CI: 0.7249 to 0.9009) with sensitivity and specificity of 80.0% and 73.2% respectively. In summary, circulating exosomal miR-342-5p and miR-574-5p have potential to serve as novel diagnostic biomarkers for early-stage LA.
Identifiants
pubmed: 32624699
doi: 10.7150/ijms.43500
pii: ijmsv17p1428
pmc: PMC7330662
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN574 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1428-1438Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Oncotarget. 2017 Jul 28;8(49):86897-86907
pubmed: 29156844
PLoS One. 2015 Oct 01;10(10):e0139233
pubmed: 26426747
Lung Cancer. 2013 Apr;80(1):45-9
pubmed: 23352032
BMC Genomics. 2013 May 10;14:319
pubmed: 23663360
Plant Mol Biol. 2012 Jan 31;:
pubmed: 22290409
Cancer Med. 2018 Jun;7(6):2370-2381
pubmed: 29673101
Cell Prolif. 2017 Dec;50(6):
pubmed: 28990243
Curr Treat Options Oncol. 2016 Oct;17(10):54
pubmed: 27523606
Oncotarget. 2015 Dec 29;6(42):44609-22
pubmed: 26587830
Am J Transl Res. 2018 Mar 15;10(3):892-900
pubmed: 29636879
Tumour Biol. 2016 Sep;37(9):11657-11665
pubmed: 27438704
PLoS One. 2014 Apr 04;9(4):e92921
pubmed: 24705249
Sci Rep. 2016 Oct 20;6:35714
pubmed: 27761023
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Molecules. 2014 Jan 27;19(2):1568-75
pubmed: 24473213
Mol Biol Rep. 2013 Feb;40(2):1325-32
pubmed: 23073777
Mol Cancer. 2017 Oct 5;16(1):156
pubmed: 28982366
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Clin Cancer Res. 2017 Sep 1;23(17):5311-5319
pubmed: 28606918
J Extracell Vesicles. 2014 Mar 26;3:
pubmed: 24683445
J Thorac Oncol. 2010 Aug;5(8):1273-8
pubmed: 20548249
Lab Chip. 2014 Oct 7;14(19):3773-80
pubmed: 25099143
Genomics Proteomics Bioinformatics. 2015 Feb;13(1):17-24
pubmed: 25724326
J Clin Oncol. 2010 Dec 20;28(36):5311-20
pubmed: 21079145
Nat Commun. 2017 Feb 17;8:14448
pubmed: 28211508
Oncogene. 2008 Dec;27 Suppl 2:S52-7
pubmed: 19956180
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
J Thorac Oncol. 2011 Mar;6(3):482-8
pubmed: 21258252
Front Med (Lausanne). 2016 Dec 23;3:69
pubmed: 28066769
PLoS One. 2012;7(11):e48278
pubmed: 23133627
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E8987-E8995
pubmed: 29073095
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Circ J. 2018 Mar 23;82(4):965-973
pubmed: 29398686
Sci Rep. 2017 Nov 10;7(1):15277
pubmed: 29127370
Br J Cancer. 2010 Oct 12;103(8):1144-8
pubmed: 20859290
Ann Oncol. 2010 Oct;21 Suppl 7:vii196-8
pubmed: 20943614